GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00432762 | Thyroid | PTC | anoikis | 18/5968 | 34/18723 | 8.65e-03 | 3.62e-02 | 18 |
GO:005085210 | Thyroid | PTC | T cell receptor signaling pathway | 52/5968 | 123/18723 | 9.58e-03 | 3.93e-02 | 52 |
GO:199084513 | Thyroid | PTC | adaptive thermogenesis | 64/5968 | 157/18723 | 1.14e-02 | 4.50e-02 | 64 |
GO:00518969 | Thyroid | PTC | regulation of protein kinase B signaling | 74/5968 | 185/18723 | 1.16e-02 | 4.58e-02 | 74 |
GO:0009896210 | Thyroid | ATC | positive regulation of catabolic process | 290/6293 | 492/18723 | 2.15e-31 | 1.94e-28 | 290 |
GO:0031331210 | Thyroid | ATC | positive regulation of cellular catabolic process | 258/6293 | 427/18723 | 2.09e-30 | 1.65e-27 | 258 |
GO:003238632 | Thyroid | ATC | regulation of intracellular transport | 203/6293 | 337/18723 | 6.16e-24 | 1.85e-21 | 203 |
GO:003450423 | Thyroid | ATC | protein localization to nucleus | 175/6293 | 290/18723 | 6.23e-21 | 1.23e-18 | 175 |
GO:1903829210 | Thyroid | ATC | positive regulation of cellular protein localization | 167/6293 | 276/18723 | 3.32e-20 | 5.38e-18 | 167 |
GO:003238825 | Thyroid | ATC | positive regulation of intracellular transport | 131/6293 | 202/18723 | 8.20e-20 | 1.24e-17 | 131 |
GO:009719335 | Thyroid | ATC | intrinsic apoptotic signaling pathway | 171/6293 | 288/18723 | 1.86e-19 | 2.67e-17 | 171 |
GO:001050632 | Thyroid | ATC | regulation of autophagy | 180/6293 | 317/18723 | 1.34e-17 | 1.46e-15 | 180 |
GO:001605525 | Thyroid | ATC | Wnt signaling pathway | 234/6293 | 444/18723 | 4.64e-17 | 4.31e-15 | 234 |
GO:019873825 | Thyroid | ATC | cell-cell signaling by wnt | 234/6293 | 446/18723 | 9.26e-17 | 8.25e-15 | 234 |
GO:005165625 | Thyroid | ATC | establishment of organelle localization | 206/6293 | 390/18723 | 2.62e-15 | 1.84e-13 | 206 |
GO:003011125 | Thyroid | ATC | regulation of Wnt signaling pathway | 177/6293 | 328/18723 | 1.83e-14 | 1.05e-12 | 177 |
GO:007233135 | Thyroid | ATC | signal transduction by p53 class mediator | 102/6293 | 163/18723 | 3.16e-14 | 1.75e-12 | 102 |
GO:001604927 | Thyroid | ATC | cell growth | 241/6293 | 482/18723 | 4.27e-14 | 2.35e-12 | 241 |
GO:003134623 | Thyroid | ATC | positive regulation of cell projection organization | 186/6293 | 353/18723 | 7.99e-14 | 4.23e-12 | 186 |
GO:190179635 | Thyroid | ATC | regulation of signal transduction by p53 class mediator | 66/6293 | 93/18723 | 1.86e-13 | 9.20e-12 | 66 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
STK11 | SNV | Missense_Mutation | | c.234G>C | p.Lys78Asn | p.K78N | Q15831 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C8-A12K-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
STK11 | SNV | Missense_Mutation | | c.336G>T | p.Gln112His | p.Q112H | Q15831 | protein_coding | tolerated(0.11) | benign(0.066) | TCGA-D8-A1Y3-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicine+cyclophosphamide | SD |
STK11 | insertion | Nonsense_Mutation | | c.178_179insA | p.Tyr60Ter | p.Y60* | Q15831 | protein_coding | | | TCGA-BH-A1EN-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
STK11 | SNV | Missense_Mutation | rs730881979 | c.526G>A | p.Asp176Asn | p.D176N | Q15831 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C5-A3HE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
STK11 | SNV | Missense_Mutation | | c.332T>A | p.Ile111Asn | p.I111N | Q15831 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C5-A7CL-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | PD |
STK11 | SNV | Missense_Mutation | | c.881C>T | p.Pro294Leu | p.P294L | Q15831 | protein_coding | deleterious(0.02) | probably_damaging(0.959) | TCGA-C5-A7CL-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | PD |
STK11 | SNV | Missense_Mutation | | c.949G>A | p.Glu317Lys | p.E317K | Q15831 | protein_coding | tolerated(0.51) | benign(0.071) | TCGA-C5-A7X3-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | SD |
STK11 | SNV | Missense_Mutation | | c.949N>A | p.Glu317Lys | p.E317K | Q15831 | protein_coding | tolerated(0.51) | benign(0.071) | TCGA-C5-A8XK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
STK11 | SNV | Missense_Mutation | novel | c.1123N>C | p.Glu375Gln | p.E375Q | Q15831 | protein_coding | tolerated(0.18) | benign(0.099) | TCGA-C5-A8XK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
STK11 | SNV | Missense_Mutation | | c.536N>A | p.Pro179Gln | p.P179Q | Q15831 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EK-A2R8-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
6794 | STK11 | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, ENZYME, TUMOR SUPPRESSOR, DRUG RESISTANCE | | EVEROLIMUS | EVEROLIMUS | 21189378 |
6794 | STK11 | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, ENZYME, TUMOR SUPPRESSOR, DRUG RESISTANCE | | SAR245409 | VOXTALISIB | 24634413 |
6794 | STK11 | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, ENZYME, TUMOR SUPPRESSOR, DRUG RESISTANCE | inhibitor | TOZASERTIB | TOZASERTIB | 19035792 |
6794 | STK11 | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, ENZYME, TUMOR SUPPRESSOR, DRUG RESISTANCE | | ATEZOLIZUMAB | ATEZOLIZUMAB | 29773717 |
6794 | STK11 | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, ENZYME, TUMOR SUPPRESSOR, DRUG RESISTANCE | | Cisplatin | CISPLATIN | 28652249 |
6794 | STK11 | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, ENZYME, TUMOR SUPPRESSOR, DRUG RESISTANCE | | Sapanisertib | SAPANISERTIB | 26574479 |
6794 | STK11 | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, ENZYME, TUMOR SUPPRESSOR, DRUG RESISTANCE | | Selumetinib | SELUMETINIB | 27821489 |
6794 | STK11 | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, ENZYME, TUMOR SUPPRESSOR, DRUG RESISTANCE | | Sirolimus | SIROLIMUS | 20142330 |
6794 | STK11 | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, ENZYME, TUMOR SUPPRESSOR, DRUG RESISTANCE | | CI-1040 | CI-1040 | 27821489 |
6794 | STK11 | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, ENZYME, TUMOR SUPPRESSOR, DRUG RESISTANCE | | RDEA119 | | 27821489 |